AtriCure, Inc. (NASDAQ:ATRC)‘s stock had its “buy” rating restated by stock analysts at Canaccord Genuity in a report issued on Monday. They presently have a $20.00 price target on the medical device company’s stock. Canaccord Genuity’s price objective points to a potential upside of 21.43% from the company’s current price.
Separately, Zacks Investment Research raised shares of AtriCure from a “hold” rating to a “strong-buy” rating and set a $21.00 target price for the company in a research report on Tuesday, November 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. AtriCure presently has an average rating of “Buy” and a consensus price target of $20.63.
AtriCure (NASDAQ:ATRC) opened at 16.47 on Monday. The firm has a 50-day moving average of $17.30 and a 200-day moving average of $16.83. AtriCure has a one year low of $13.44 and a one year high of $20.40. The stock’s market capitalization is $547.45 million.
In other AtriCure news, Director Elizabeth D. Krell sold 10,000 shares of the business’s stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $19.73, for a total transaction of $197,300.00. Following the completion of the transaction, the director now directly owns 24,162 shares of the company’s stock, valued at approximately $476,716.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 10.00% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Morgan Stanley raised its position in AtriCure by 136.4% in the third quarter. Morgan Stanley now owns 9,956 shares of the medical device company’s stock worth $157,000 after buying an additional 5,745 shares during the last quarter. BlackRock Group LTD raised its position in AtriCure by 5.5% in the third quarter. BlackRock Group LTD now owns 10,969 shares of the medical device company’s stock worth $174,000 after buying an additional 576 shares during the last quarter. BlackRock Advisors LLC raised its position in AtriCure by 11.5% in the second quarter. BlackRock Advisors LLC now owns 14,654 shares of the medical device company’s stock worth $207,000 after buying an additional 1,517 shares during the last quarter. American International Group Inc. raised its position in AtriCure by 8.9% in the second quarter. American International Group Inc. now owns 18,093 shares of the medical device company’s stock worth $256,000 after buying an additional 1,478 shares during the last quarter. Finally, Advisory Services Network LLC purchased a new position in AtriCure during the third quarter worth about $260,000. 79.35% of the stock is owned by hedge funds and other institutional investors.
AtriCure Company Profile
AtriCure, Inc is a medical device company providing atrial fibrillation (Afib) solutions. The Company’s segment develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. The Company has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.